Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity

Alessandro Inno, Giulio Metro, Paolo Bironzo, Antonio M. Grimaldi, Elisabetta Grego, Vincenzo Di Nunno, Virginia Picasso, Francesco Massari, Stefania Gori

Research output: Contribution to journalReview article

Abstract

Immune checkpoint inhibitors have emerged as an effective treatment for several tumor types and their use in clinical practice is expected to further increase in the immediate future. Although these agents are well tolerated, they are associated with a peculiar spectrum of toxicity, which is immune mediated and may potentially affect every organ. However, immune-related adverse events are mostly reversible if promptly diagnosed and adequately treated. Therefore, it is crucial that medical oncologists know how to diagnose and treat immune-related adverse events. This review focuses on the pathogenesis, clinical manifestations and management of immune-related toxicity of anti-CTLA-4 and anti-PD-1 antibodies.

Original languageEnglish
Pages (from-to)405-421
Number of pages17
JournalTumori
Volume103
Issue number5
DOIs
Publication statusPublished - Sep 1 2017

    Fingerprint

Keywords

  • Immune checkpoint inhibitors
  • Immune-related adverse events
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017). Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori, 103(5), 405-421. https://doi.org/10.5301/tj.5000625